1244039-95-9Relevant academic research and scientific papers
KRAS G12C Inhibitor and application thereof
-
Paragraph 0251-0253, (2021/03/31)
The invention discloses a novel KRAS G12C inhibitor, wherein the compound as shown in a formula I, and an isomer or pharmaceutically acceptable salt thereof have the following structure. The compoundas shown in the formula I and the composition thereof di
TRANSGLUTAMINASE 2 (TG2) INHIBITORS
-
Paragraph 00786, (2020/03/02)
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
-
Page/Page column 49, (2011/04/14)
The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
DISUBSTITUTED IMIDAZOLE DERIVATIVES AS MODULATORS OF RAF KINASE
-
Page/Page column 75, (2010/09/18)
Novel substituted imidazole compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with an additional agent f
